论文部分内容阅读
目的探讨吉西他滨与奈达铂联合治疗晚期肺鳞癌的临床效果。方法 80例晚期肺鳞癌患者,随机分为观察组和对照组,各40例。观察组患者采用吉西他滨联合奈达铂的化疗方案进行治疗,对照组患者采用吉西他滨联合顺铂的化疗方案进行治疗。比较两组患者的近期临床疗效及不良反应情况。结果经过2个周期化疗,观察组总有效率为47.50%,对照组为45.00%,比较差异无统计学意义(P>0.05)。观察组患者化疗产生的不良反应情况优于对照组,差异有统计学意义(P<0.05)。结论吉西他滨联合奈达铂治疗晚期肺鳞癌的临床疗效与吉西他滨联合顺铂的疗效相当,但奈达铂引起的不良反应相比顺铂较少,毒副反应轻,耐受性高,值得临床广泛应用。
Objective To investigate the clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced squamous cell carcinoma of the lung. Methods 80 patients with advanced squamous cell carcinoma of the lung were randomly divided into observation group and control group, 40 cases in each. Patients in the observation group were treated with the chemotherapy regimen of gemcitabine combined with nedaplatin, while patients in the control group were treated with the chemotherapy regimen of gemcitabine and cisplatin. The recent clinical efficacy and adverse reactions of the two groups were compared. Results After two cycles of chemotherapy, the total effective rate was 47.50% in the observation group and 45.00% in the control group, with no significant difference (P> 0.05). Adverse reactions induced by chemotherapy in observation group were better than those in control group, the difference was statistically significant (P <0.05). Conclusion The clinical efficacy of gemcitabine combined with nedaplatin in the treatment of advanced squamous cell carcinoma of the lung is comparable to that of gemcitabine combined with cisplatin. However, adverse effects caused by nedaplatin are less than that of cisplatin, with mild toxic side effects and high tolerance, which is worth clinical widely used.